Tissue Microarrays

1. Introduction

During the last decades, major scientific efforts have focused on understanding the structure and functional organization of the human genome. The completion of the Human Genome Project in 2001 marked a turning point in genomic research by providing the complete base sequences of thousands of human genes. This achievement, combined with the development of cDNA microarray technologies, enabled large-scale analysis of gene expression patterns across the entire transcriptome.

These technologies allowed researchers to compare gene expression profiles between healthy and diseased tissues, leading to the identification of thousands of genes potentially involved in various pathological processes. Despite their usefulness, cDNA arrays present several important limitations.

A major constraint is the requirement for fresh or unfixed tissue samples, which are typically obtained from prospective studies. Such samples often lack long-term clinical follow-up data, limiting their usefulness for retrospective clinical research. In addition, large-scale cDNA array experiments can be technically demanding and costly, restricting their application in routine clinical studies.

For these reasons, researchers require efficient methods to validate candidate biomarkers using archived clinical tissue samples. Pathology laboratories store large collections of formalin-fixed paraffin-embedded (FFPE) tissues, many of which are associated with extensive clinical data. These specimens represent an invaluable resource for retrospective molecular studies.

However, achieving reliable statistical conclusions often requires the analysis of thousands of tissue samples. Traditional molecular biology techniques used for large-scale validation include:

• Northern blot analysis

• Western blot analysis

• Protein arrays

• High-throughput real-time PCR

Although these approaches support high-throughput analysis, they require tissue homogenization before molecular evaluation. This process destroys the spatial organization of the tissue and prevents the identification of the specific cell types responsible for gene expression.

To preserve tissue architecture and cellular localization, in situ molecular techniques are widely used in molecular pathology. These include:

• Immunohistochemistry (IHC) for protein detection

• RNA in situ hybridization (RNA-ISH) for RNA localization

• Fluorescence in situ hybridization (FISH) for DNA or RNA analysis

These techniques enable researchers to analyze molecular targets directly within intact tissues. However, performing large-scale studies with conventional histological sections is time-consuming, labor-intensive, and inefficient.

Another limitation is that a standard tissue block generally produces fewer than 200 histological sections. Large experimental studies requiring numerous analyses can therefore quickly exhaust valuable archived samples.

To address these challenges, researchers developed Tissue Microarray (TMA) technology, an innovative approach that allows the simultaneous analysis of hundreds of tissue samples on a single microscope slide. This method represents an advancement of earlier strategies, such as the “sausage block” and “drinking straw” techniques previously used for analyzing multiple tissues together.

2. Tissue Microarray Technology

2.1 Principle of TMA Construction

Tissue Microarray (TMA) technology significantly improves the efficiency of large-scale in situ tissue analysis. Using this method, up to 1000 individual tissue samples can be analyzed simultaneously on a single microscope slide.

The process involves transferring small      cylindrical tissue cores from multiple donor tissue blocks into a single recipient paraffin block.

TMA Construction Steps

• Selection of donor tissue samples
  Pathologists identify appropriate tissue blocks containing representative regions of interest, such as tumor areas.

• Extraction of tissue cores
  Small cylindrical samples, typically 0.6 mm in diameter, are removed from donor paraffin blocks using specialized tissue arraying instruments.

• Assembly into a recipient block
  The extracted cores are inserted into predefined coordinates in an empty recipient paraffin block, forming an organized array.

• Sectioning and slide preparation
  Thin sections are cut from the TMA block using a microtome and mounted onto microscope slides for analysis.

TMA sections can then be analyzed using various molecular techniques, including:

• Immunohistochemistry (IHC)

• Fluorescence in situ hybridization (FISH)

• RNA in situ hybridization (RNA-ISH)

Importantly, most existing laboratory protocols can be applied to TMA sections without significant modification.

2.2 Practical Considerations in TMA Construction

The extraction of small tissue cores allows a large number of samples to be collected from a single donor block while minimizing damage to the original specimen. In many cases, dozens of cores can be taken from a tumor block without compromising its diagnostic integrity.

However, the most demanding part of TMA production is logistical organization rather than the physical array construction itself.

Key steps include:

• Identification of suitable histological samples from pathology databases

• Retrieval and review of archived slides by a pathologist

• Marking representative tissue regions for sampling

• Collection of corresponding paraffin blocks

• Creation of databases containing clinical and histological information

Large TMA projects may involve the handling of thousands of paraffin blocks and tens of thousands of histological slides.

Interestingly, the physical construction of the microarray itself usually represents less than 5% of the total workload.

2.3 TMA Construction Instruments

Most tissue microarray devices use two precision needles with slightly different diameters.

• The smaller needle creates holes in the recipient paraffin block.

• The larger needle extracts tissue cylinders from donor blocks and transfers them into these holes.

Standard microtomes can then be used to cut sections from the completed TMA block. To reduce sample loss during sectioning, adhesive tape systems are sometimes used to stabilize the sections.

2.4 Paraffin and Frozen Tissue Microarrays

Most TMAs are constructed using paraffin-embedded tissues, primarily because they are widely available in pathology archives and are relatively easy to handle.

However, frozen tissue samples can also be used to construct TMAs. In these cases, embedding is performed using **Tissue-Tek O.C.T. Compound instead of paraffin.

Frozen TMAs provide several advantages:

• They allow the use of antibodies that do not perform well on paraffin sections.

• They enable the analysis of protein activation states, such as phosphorylation.

• They exhibit lower autofluorescence, making them more suitable for fluorescence-based protein detection.

However, frozen tissue arrays are technically more delicate, and arraying needles are more prone to bending or damage.

3. Representativity of Tissue Microarrays

One of the most frequently discussed concerns regarding TMA technology is whether small tissue cores accurately represent the biological characteristics of the entire tumor.

Despite the small diameter of TMA cores (typically 0.6 mm), numerous studies have demonstrated that TMAs provide high concordance with traditional whole tissue sections.

Tissue heterogeneity remains an important consideration. For example,Hodgkin lymphoma contains relatively few malignant cells surrounded by a large number of reactive inflammatory cells. In such cases, one might expect that small tissue cores would not capture representative tumor features.

Nevertheless, several studies have shown that even highly heterogeneous tumors such as Hodgkin lymphoma can be reliably analyzed using TMA technology, producing results comparable to those obtained from full tissue sections.

Many comparative studies evaluating immunohistochemical analyses performed on both TMAs and whole sections have demonstrated a high degree of agreement between the two methods.

Research also indicates that taking two or three cores from different tumor regions improves representativity compared with using a single sample. Increasing the number of cores beyond four or five provides only minimal additional improvement.

Another important point is that conventional histological sections themselves represent only a very small portion of the total tumor volume, suggesting that complete representativity is rarely achieved even with traditional methods.

Therefore, the most relevant evaluation of TMA reliability is whether known associations between molecular markers and clinical outcomes can be reproduced using TMA datasets. Multiple studies have confirmed this capability.

Examples include correlations between:

• HER2 alterations and breast cancer survival

• Ki-67 proliferation index and prognosis in bladder cancer

• Vimentin expression and prognosis in kidney cancer

These results demonstrate that TMA technology is a robust and reliable tool for large-scale molecular pathology research.

4. Applications of Tissue Microarrays in Research

Although TMAs can be used in many types of biological research, their most common applications are currently found in oncology. Three main categories of TMA designs are commonly used:

4.1 Prevalence TMAs

Prevalence TMAs contain tissue samples from multiple tumor types and are used to determine the frequency of a specific molecular marker within different cancers.

For example, multitumor TMAs have been used to analyze gene amplifications such as:

• Cyclin D1

• MYC

• HER2

Large-scale prevalence TMAs may contain thousands of samples representing more than one hundred tumor types, allowing comprehensive studies of molecular epidemiology.

Normal tissue TMAs can also be constructed to investigate protein distribution in healthy tissues, which is particularly important during drug development to predict potential side effects.

4.2 Progression TMAs

Progression TMAs contain tissue samples representing different stages of a particular disease.

For instance, a breast cancer progression TMA may include:

• Normal breast tissue

• Benign lesions

• Carcinoma in situ

• Invasive tumors

• Metastatic lesions

Such arrays allow researchers to study the molecular events involved in tumor initiation, progression, and metastasis.

4.3 Prognostic TMAs

Prognostic TMAs include tumor samples associated with clinical follow-up data, making them valuable for evaluating the relationship between molecular alterations and patient outcomes.

These arrays have been used extensively in cancers such as:

• Breast cancer

• Prostate cancer

• Brain tumors

• Liver cancer

• Colorectal cancer

• Malignant melanoma

Studies using prognostic TMAs have identified important associations between molecular markers and survival or disease progression.

5. Future Developments

Tissue microarray technology provides a powerful platform for validating candidate biomarkers identified through high-throughput genomic and proteomic studies.

Initially limited to a few research institutions, TMA technology is now widely accessible through universities, research institutes, and specialized organizations.

In the future, one of the major challenges will be the analysis and interpretation of large numbers of TMA samples. As a result, automated imaging and computational analysis systems are being developed to improve throughput.

Advanced technologies such as automated fluorescence quantification and digital pathology systems are expected to play a crucial role in improving the efficiency of TMA-based research.